Biologics 101 (oncology)
Note: This page is educational and reflects the state of the literature in 2025. It does not replace medical advice.
TL;DR
Biologics are drugs derived from living systems or composed of large biomolecules — distinct from small-molecule chemistry. In oncology they are now the mainstream of new approvals: monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), bispecifics and immune engagers, engineered cellular therapies (CAR-T, CAR-NK, TIL), and therapeutic vaccines. They behave very differently from chemotherapy in terms of pharmacology, manufacturing, regulation, and cost — and they require different mental models for everyone working with them, including data and platform teams.
1. Why "biologics" is its own category
Compared with small molecules:
- Made by cells, not chemists. CHO/HEK cell lines, E. coli, yeast, or even patient-derived T cells. Production is biological, not synthetic.
- Large and complex. A typical mAb is ~150 kDa; a small-molecule drug is ~0.3 kDa. Folding, glycosylation, and post-translational modifications matter.
- Targeted by design. They bind defined molecular targets — typically extracellular — instead of diffusing into cells.
- Cold chain and logistics matter. Many biologics require −20 °C or colder; cellular therapies require living-cell handling.
- Manufacturing IS the product. Two batches of the same biologic are not chemically identical the way two pills are. This is the basis of biosimilars (not generics).
- Pricing and access are dominated by manufacturing complexity and per-patient personalization.
For technologists building data platforms in oncology, this means handling product-attribute data (lot, vial, cell line, modality), managing chain-of-identity for cellular therapies, and understanding why "the drug" cannot always be reduced to a simple SKU.
2. The major classes
2.1 Monoclonal antibodies (mAbs)
A protein engineered to bind a specific target with high affinity. Categories by mechanism:
- Receptor blockade — anti-HER2 (trastuzumab), anti-EGFR (cetuximab, panitumumab).
- Anti-angiogenic — anti-VEGF (bevacizumab).
- Immune checkpoint inhibitors — anti-PD-1 (pembrolizumab, nivolumab), anti-PD-L1 (atezolizumab, durvalumab), anti-CTLA-4 (ipilimumab), and emerging anti-LAG-3 / TIGIT.
- Tumor-cell ADCC inducers — rituximab (anti-CD20), trastuzumab.
mAbs were the first wave of biologic oncology drugs and remain dominant in approvals. Sources: [1]
2.2 Antibody-drug conjugates (ADCs)
A monoclonal antibody covalently linked, via a chemical linker, to a cytotoxic payload. The antibody steers the toxin to cells expressing the target antigen — the "biological missile" idea. Sources: [1], [2]
Key engineering choices:
- Antibody — affinity, internalization, target expression in normal vs. tumor tissue.
- Linker — stable in circulation, cleavable inside the target cell (cathepsin-B-cleavable, glutathione-cleavable, etc.).
- Payload — often a microtubule poison (auristatins, maytansinoids), DNA-damaging agent (calicheamicin, PBD dimer), or topoisomerase-I inhibitor (DXd, exemplified by trastuzumab deruxtecan).
- Drug-to-antibody ratio (DAR) — too low = underdosed; too high = aggregation, toxicity.
By 2025, more than a dozen ADCs are FDA-approved across breast, urothelial, gastric, lung, lymphoma, leukemia, and other indications, with over 100 candidates in clinical development. Sources: [1], [2]
2.3 Bispecific antibodies and T-cell engagers
A single antibody that binds two targets simultaneously. Most prominent oncology design: BiTE / T-cell engager — one arm binds a tumor antigen, the other binds CD3 on T cells, forcing immune synapse formation. Examples: blinatumomab (CD19 × CD3) in B-ALL; teclistamab (BCMA × CD3) in multiple myeloma; tarlatamab (DLL3 × CD3) in small-cell lung cancer. Sources: [3]
2.4 Engineered cellular therapies
Living cells reprogrammed to attack cancer. The most established class is CAR-T — autologous T cells transduced ex vivo with a chimeric antigen receptor against a tumor antigen. Six FDA-approved CAR-T products as of late 2024, all in hematologic malignancies.Adjacent and emerging: CAR-NK, TIL (tumor-infiltrating lymphocytes; first solid-tumor cellular therapy approval, lifileucel in melanoma, 2024), engineered TCR therapies (e.g., afami-cel in synovial sarcoma). Sources: [4], [5]
For deeper coverage, see CAR-T cell breakthroughs.
2.5 Therapeutic vaccines
Designed to induce anti-tumor immunity rather than block existing immune signals. Modalities include peptide vaccines, dendritic-cell vaccines, viral vectors, and mRNA personalized neoantigen vaccines — a fast-moving area driven by COVID-era mRNA infrastructure.Most therapeutic vaccines are still in trials and most often combined with checkpoint inhibitors. Sources: [6]
2.6 Oncolytic viruses
Engineered viruses that selectively replicate in tumor cells, lysing them and stimulating immune response (e.g., talimogene laherparepvec / T-VEC for melanoma). See Oncolytic virus therapy.
3. Biosimilars (not generics)
When a biologic's patent expires, follow-on versions are biosimilars, not generics — because the molecules cannot be made identical. Regulators (FDA, EMA, ANVISA) require:
- Comparable structure (mass spec, glycan analysis, biophysics).
- Comparable function (binding, ADCC, complement activation).
- Comparable PK/PD in humans.
- A confirmatory clinical trial in at least one approved indication — with extrapolation to others when scientifically justified.
Key brands with multiple biosimilars: trastuzumab, rituximab, bevacizumab. Biosimilars meaningfully lower cost and have been a major access lever in Brazil's SUS.
4. What technologists should know
Working with biologics introduces concerns absent in small-molecule pipelines:
- Target biology drives toxicity as much as efficacy — a perfect mAb against an antigen also expressed on cardiac tissue is a cardiotoxin.
- Manufacturing is part of the product — lot variability, cell-line drift, glycosylation differences between batches.
- Cold chain monitoring — temperature excursions can deactivate a $100k+ vial; IoT and data integration matter.
- Chain of identity / chain of custody for autologous cellular therapies — each apheresis bag, manufacturing slot, and infusion bag must be traceable to one specific patient.
- Cost and access — biologics dominate oncology drug spend; pricing models, biosimilar policy, and regional approval timelines materially affect patient outcomes.
- Trials and endpoints — biologic responses (immune-related, deep durable remissions) often need different endpoints than chemo-era PFS/OS thinking. See Clinical trials.
5. Brazilian context
- ANVISA has its own biosimilar pathway (RDC 55/2010, updated framework continuing).
- The SUS has incorporated several biologic oncology drugs over the last decade, but access timelines and regional variation remain a challenge.
- Hemorio, INCA, and academic centers have developed academic CAR-T programs — important for cost reduction and local capacity, beyond commercial products. Sources: [4]
6. Common pitfalls when reading biologic-trial press releases
- Confusing ORR with cure — high response rates do not equal durable benefit.
- Treating single-arm Phase II data in a "first-in-class" agent as if it were Phase III.
- Ignoring immune-related adverse events (irAEs) — endocrine, GI, pulmonary, neurologic.
- Forgetting CAR-T-specific toxicities — cytokine release syndrome (CRS), ICANS, prolonged cytopenias.
- Generalizing from monogeneic hematological success (e.g., CD19 in B-ALL) to solid tumors with antigen heterogeneity.
See also
- CAR-T cell breakthroughs
- Immuno basics & checkpoints
- Emerging therapies
- Nanotechnology delivery
- Clinical trials 101
References
- Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduct Target Ther 2022;7:93. PMID 35318309. https://doi.org/10.1038/s41392-022-00947-7
- Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov 2023;22:641-661. PMID 37308581. https://doi.org/10.1038/s41573-023-00709-2
- Meyer ML, Fitzgerald BG, Paz-Ares L, et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet 2024;404:803-822. PMID 39121882. https://doi.org/10.1016/S0140-6736(24)01029-8
- Brudno JN, Maus MV, Hinrichs CS. CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review. JAMA 2024;332:1924-1935. PMID 39495525. https://doi.org/10.1001/jama.2024.19462
- Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol 2024;21:1089-1108. PMID 39134804. https://doi.org/10.1038/s41423-024-01207-0
- Sayour EJ, Boczkowski D, Mitchell DA, Nair SK. Cancer mRNA vaccines: clinical advances and future opportunities. Nat Rev Clin Oncol 2024;21:489-500. PMID 38760500. https://doi.org/10.1038/s41571-024-00902-1
- A.C. Camargo Cancer Center. https://accamargo.org.br
- Fundação do Câncer (Brasil). https://www.cancer.org.br/
- Ministério da Saúde / BVS. ABC do câncer. https://bvsms.saude.gov.br/bvs/publicacoes/abc_do_cancer.pdf
- U.S. National Cancer Institute. https://www.cancer.gov/about-cancer/understanding/what-is-cancer
- American Cancer Society. https://www.cancer.org/cancer.html
- Cleveland Clinic. Cancer (overview). https://my.clevelandclinic.org/health/diseases/12194-cancer